Myeloproliferative neoplasier (MPN)
Myeloproliferative neoplasier (MPN)
Sist oppdatert: 27.11.2025
Mer informasjon
Utgiver: Helsedirektoratet
Versjon: 1.0
Tidligere versjoner
Foreslå endringer/gi kommentarer
Dette kapittelet omtaler diagnostikk og behandling av polycytemia vera, essensiell trombocytose, prefibrotisk myelofibrose, primær myelofibrose, sekundær myelofibrose og uklassifiserbare myeloproliferative tilstander.
Mens kronisk myelogen leukemi er omtalt i eget kapittel, omtales ikke kronisk nøytrofil leukemi og kronisk eosinofil leukemi i handlingsprogrammet. Atypiske myeloproliferative sykdommer og MDS/MPN overlappssyndromer er heller ikke dekket i her.
Kapittelet er i henhold til 5. utgave av WHO klassifikasjon (2022) for diagnostikk. I tillegg til 5. utgave av WHO klassifikasjonen foreligger det fra 2022 også et alternativt klassifikasjonssystem, International Consensus Classification (ICC). For de myeloproliferative sykdommene er det ingen forskjeller mellom WHO og ICC er klassifikasjonene, og nytt klassifiseringssystem har derfor ingen betydning for dette handlingsprogrammet.
For korrekt klassifikasjon er det viktig å bruke de diagnostiske kriteriene til ICC og WHO. Kapittelet er også oppdatert i henhold til nye retningslinjer for risikostratifisering og behandling av MPN.
Referanser
Ajufo, H. O., Waksal, J. A., Mascarenhas, J. O., & Rampal, R. K. (2023). Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges.
Therapeutic advances in hematology,
14, 20406207231177282.
Alvarez-Larrán, A., Sant'Antonio, E., Harrison, C., Kiladjian, J. J., Griesshammer, M., Mesa, R., ... Barbui, T. (2021). Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet.
The Lancet. Haematology,
8(9), e658-e665.
Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H. M., ... Tefferi, A. (2022). International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
Blood,
140(11), 1200-1228.
Barbui, T., De Stefano, V., Carobbio, A., Iurlo, A., Alvarez-Larran, A., Cuevas, B., ... Mascarenhas, J. (2021). Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients.
Leukemia,
35(10), 2989-2993.
Birgegård, G., Besses, C., Griesshammer, M., Gugliotta, L., Harrison, C. N., Hamdani, M., ... Kiladjian, J. J. (2018). Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.
Haematologica,
103(1), 51-60.
Gagelmann, N., Ditschkowski, M., Bogdanov, R., Bredin, S., Robin, M., Cassinat, B., ... Kröger, N. (2019). Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation.
Blood,
133(20), 2233-2242.
Gagelmann, N., Hobbs, G. S., Campodonico, E., Helbig, G., Novak, P., Schroeder, T., ... Kröger, N. (2024). Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis.
American journal of hematology,
99(5), 844-853.
Gisslinger, H., Gotic, M., Holowiecki, J., Penka, M., Thiele, J., Kvasnicka, H. M., ... Petrides, P. E. (2013). Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Blood,
121(10), 1720-8.
Guglielmelli, P., Carobbio, A., Rumi, E., De Stefano, V., Mannelli, L., Mannelli, F., ... Barbui, T. (2020). Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis.
Blood cancer journal,
10(2), 21.
Harrison, C. N., & Robinson, S. E. (2011). Myeloproliferative disorders in pregnancy.
Hematology/oncology clinics of North America,
25(2), 261-75, vii.
Harrison, C. N., Schaap, N., Vannucchi, A. M., Kiladjian, J. J., Jourdan, E., Silver, R. T., ... Mesa, R. A. (2020). Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
American journal of hematology,
95(6), 594-603.
Landtblom, A. R., Bower, H., Andersson, T. M., Dickman, P. W., Samuelsson, J., Björkholm, M., ... Hultcrantz, M. (2018). Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.
Leukemia,
32(10), 2203-2210.
Mesa, R. A., Kiladjian, J. J., Catalano, J. V., Devos, T., Egyed, M., Hellmann, A., ... Gotlib, J. (2017). SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Journal of Clinical Oncology,
35(34), 3844-3850.
Pardanani, A., Harrison, C., Cortes, J. E., Cervantes, F., Mesa, R. A., Milligan, D., ... Tefferi, A. (2015). Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
JAMA oncology,
1(5), 643-51.
Pardanani, A., Tefferi, A., Masszi, T., Mishchenko, E., Drummond, M., Jourdan, E., ... Harrison, C. (2021). Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
British Journal of Haematology,
195(2), 244-248.
Tefferi, A., Mudireddy, M., Gangat, N., Hanson, C. A., Ketterling, R. P., Pardanani, A., & Nagorney, D. M. (2017). Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis.
American journal of hematology,
92(11), 1187-1192.
Verstovsek, S., Gerds, A. T., Vannucchi, A. M., Al-Ali, H. K., Lavie, D., Kuykendall, A. T., ... Mesa, R. (2023). Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Lancet,
401(10373), 269-280.
Verstovsek, S., Mesa, R., Gupta, V., Lavie, D., Dubruille, V., Cambier, N., ... Harrison, C. (2023). Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
Blood advances,
7(14), 3582-3591.
WHO Classification of Tumours Editorial Board, (2022).
Haematolymphoid tumours. [nettdokument - beta versjon ahead of print]. Lyon: International Agency for Research on Cancer. Hentet 2023 fra
https://tumourclassification.iarc.who.int/welcome/
- Gå til avsnitt
- Referanser
Lukk
Kopiert
